全文获取类型
收费全文 | 35430篇 |
免费 | 2260篇 |
国内免费 | 372篇 |
专业分类
耳鼻咽喉 | 334篇 |
儿科学 | 494篇 |
妇产科学 | 403篇 |
基础医学 | 4602篇 |
口腔科学 | 1020篇 |
临床医学 | 2506篇 |
内科学 | 8250篇 |
皮肤病学 | 903篇 |
神经病学 | 2421篇 |
特种医学 | 1363篇 |
外国民族医学 | 2篇 |
外科学 | 6011篇 |
综合类 | 783篇 |
一般理论 | 1篇 |
预防医学 | 1209篇 |
眼科学 | 699篇 |
药学 | 2813篇 |
4篇 | |
中国医学 | 249篇 |
肿瘤学 | 3995篇 |
出版年
2023年 | 202篇 |
2022年 | 443篇 |
2021年 | 727篇 |
2020年 | 447篇 |
2019年 | 542篇 |
2018年 | 659篇 |
2017年 | 623篇 |
2016年 | 629篇 |
2015年 | 683篇 |
2014年 | 875篇 |
2013年 | 1100篇 |
2012年 | 1598篇 |
2011年 | 1736篇 |
2010年 | 1070篇 |
2009年 | 955篇 |
2008年 | 1506篇 |
2007年 | 1507篇 |
2006年 | 1516篇 |
2005年 | 1594篇 |
2004年 | 1500篇 |
2003年 | 1574篇 |
2002年 | 1489篇 |
2001年 | 1420篇 |
2000年 | 1424篇 |
1999年 | 1265篇 |
1998年 | 447篇 |
1997年 | 372篇 |
1996年 | 338篇 |
1995年 | 297篇 |
1994年 | 268篇 |
1993年 | 248篇 |
1992年 | 834篇 |
1991年 | 735篇 |
1990年 | 745篇 |
1989年 | 705篇 |
1988年 | 716篇 |
1987年 | 624篇 |
1986年 | 618篇 |
1985年 | 600篇 |
1984年 | 394篇 |
1983年 | 329篇 |
1982年 | 152篇 |
1979年 | 319篇 |
1978年 | 205篇 |
1977年 | 153篇 |
1975年 | 150篇 |
1974年 | 213篇 |
1973年 | 151篇 |
1972年 | 165篇 |
1971年 | 147篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
2.
3.
4.
目的:探讨微波配合序贯扩肛治疗陈旧性肛裂的临床疗效。方法:选取陈旧性肛裂患者78例,随机分为对照组和治疗组,每组各39例。对照组患者采用后卫内括约肌部分切断治疗,治疗组患者采用微波配合序贯扩肛治疗。结果:观察组患者术中出血量、切口愈合时间均少于对照组(P<0.05),并发症发生率低于对照组(P<0.05)。结论:采用微波配合序贯扩肛治疗陈旧性肛裂,临床疗效显著。 相似文献
5.
Kensuke Kudou Hiroshi Saeki Yuichiro Nakashima Shun Sasaki Tomoko Jogo Kosuke Hirose Qingjiang Hu Yasuo Tsuda Koichi Kimura Ryota Nakanishi Nobuhide Kubo Koji Ando Eiji Oki Tetsuo Ikeda Yoshihiko Maehara 《American journal of surgery》2019,217(4):757-763
Background
There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).Methods
Patients with AEG and UGC who were judged as non-sarcopenic before surgery were reassessed the presence of postoperative development of sarcopenia 6 months after surgery. Patients were divided into the development group or non-development group, and clinicopathological factors and prognosis between these two groups were analyzed.Results
The 5-year overall survival rates were significantly poorer in the development group than non-development group (68.0% vs. 92.6%, P?=?0.0118). Multivariate analyses showed that postoperative development of sarcopenia was an independent prognostic factor for poor overall survival (P?=?0.0237).Conclusions
Postoperative development of sarcopenia was associated with a poor prognosis in patients with AEG and UGC. 相似文献6.
Tien‐Yao Tsai Iat‐Lon Leong Ka‐Shun Cheng Lian‐Ru Shiao Tzu‐Hui Su Kar‐Lok Wong Paul Chan Yuk‐Man Leung 《Fundamental & clinical pharmacology》2019,33(1):52-62
A pathological feature in atherosclerosis is the dysfunction and death of vascular endothelial cells (EC). Oxidized low‐density lipoprotein (LDL), known to accumulate in the atherosclerotic arterial walls, impairs endothelium‐dependent relaxation and causes EC apoptosis. A major bioactive ingredient of the oxidized LDL is lysophosphatidylcholine (LPC), which at higher concentrations causes apoptosis and necrosis in various EC. There is hitherto no report on LPC‐induced cytotoxicity in brain EC. In this work, we found that LPC caused cytosolic Ca2+ overload, mitochondrial membrane potential decrease, p38 activation, caspase 3 activation and eventually apoptotic death in mouse cerebral bEND.3 EC. In contrast to reported reactive oxygen species (ROS) generation by LPC in other EC, LPC did not trigger ROS formation in bEND.3 cells. Pharmacological inhibition of p38 alleviated LPC‐inflicted cell death. We examined whether heparin could be cytoprotective: although it could not suppress LPC‐triggered Ca2+ signal, p38 activation and mitochondrial membrane potential drop, it did suppress LPC‐induced caspase 3 activation and alleviate LPC‐inflicted cytotoxicity. Our data suggest LPC apoptotic death mechanisms in bEND.3 might involve mitochondrial membrane potential decrease and p38 activation. Heparin is protective against LPC cytotoxicity and might intervene steps between mitochondrial membrane potential drop/p38 activation and caspase 3 activation. 相似文献
7.
8.
9.
10.